Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to resp

WA.TRE

Substitute for form 1449A/PTO

NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet 3

Сотр	HO	g	
Application Number	10/049,208	四	
Filing Date	February 8, 200	2 = 1	,
First Named Inventor	Patrick Bernarde	lli 😘	
Group Art Unit	1614	숣	
Examiner Name		9	
Attorney Docket Number	A0000135-01-HM	B $\frac{1}{12}$	5

	U.S. PATENT DOCUMENTS						
Examiner nitials	Cite No.1	U.S. Peten Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
,							
		,					

			7.				
		;					
-							
		~					
			1 1				
					†	<u> </u>	
			1 1		-1		
				. ***			

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite 1	c e³	Foreign Patent Docu Number ⁴	ment Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
KX		WO	96 08455	Α	Abbott Laboratories	03/21/1996		
KI		EP	0342615	Α	Istituto Guido Donegani	11/23/1989		
KY		DE	4,101,334	Α	Chemie Ag Bitterfield-Wolfen	08/08/1991		
		-	÷-					┼
		-				 -		+
			·····		· · · · · · · · · · · · · · · · · · ·			
								ļ

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FILED ON: 2/8/2002

DOCKET NO.: A0000135-01-HMB **USSN: 10/049,208**

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	- (
ease type a plus sign (+) inside this box	→	+

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control bumber.

ubstitute for form 1449B/PTO FORMATION DISCLOSURE TATEMENT BY APPLICANT


Complete if Kn wn 10/049,208 **Application Number** February 8, 2002 **Filing Date** Patrick Bernardelli First Named Inventor 1614 **Group Art Unit Examiner Name** Attorney Docket Number A0000135-01-HMB

(use as many sheets as necessary) of Sheet

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
KΝ		Yoon Jing Lee, Epoxidation of Olefins with H202 Catalyzed By An Electronegatively-substituted Iron Pdorphyrin Complex In Aprotic Solvent, Chemistry Letters, No. 8, pgs 837-838 (1998)	
1		Still, et al., Rapid Chromatographic Technique for Preparative Separation with Moderate Resolution, J. Org. Chem, 43: 2923 (1978)	
	•	Felix, et al., Quinazolines and 1,4-Benzodiazepines. XLIII(1). Oxidations with Ruthenium Tetroxide, J. Heterocycl. Chem, 5: 731 (1968)	
	-	Sulkowski, et al., The Formation and Subsequent Rearrangment of 7-Chloro-5-phenyl-3,1,4-benzoxadiazepin-2(1H)-one, J. Org. Chem., 27: 4424 (1962)	
	·	Battioni, et al., Monooxygenase-like Oxidation of Hydrocarbons by H2O2 Catalyzed by Manganese Porphyrins and Imidazole: Selection of the Best Catalytic System and Nature of the Active Oxygen Species, J. Am. Chem. Soc., 110: 8462 (1988)	
		Thellend, et al., Ammonium Acetate as a very Sime and Efficient Cocatalyst for Manganese Porphyrin-catalysed Oxygenation of Hydroarbons by Hydrogetn Peroxide, J. Chem. Soc., Chem. Comm., 1035 (1994)	:
		Ebel, V.S., et al., Analytik und Synthese wichtiger 3-Hydroxy-5-phenyl-1,4-benzodiazepin-2-on-Derivate, ArzneimForsch., 29:1317 (1979)	
		Rocha Gonsalves, et al., State of the art in the development of biomimetic oxidation catalysts, J. Mol. Catal. A: Chem., 113:209 (1996)	
		Frohlic, L. et al., Moglichkeiten des Einsatzes biomimetischer Systeme zur Monooxygenierung von Wirk-und Arzneistoffen, Pharm. Ind. 59:803 (1997)	
	•	Chorghade, M.S., et al., Metalloporphyrins as chemical mimics of cytochrome P-450 systems, Pure Appl. Chem. 68:753 (1996)	
		Meunier, B., Metalloporphyrins and Versatile Catalysts for Oxidation Reactions and Oxidative DNA Cleavage, Chem Rev., 92:1411 (1992)	

Examiner Signature	<i>/</i> #	- Retay MAR	Date Considered	May 14, 2003

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please	type	a plus	sign	(+) i	inside	this	box	→	+
--------	------	--------	------	-------	--------	------	-----	---	---

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control pamber.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 3

Com	pl t if Known	(5)
Application Number	10/049,208	0
Filing Date	February 8, 2002	
First Named Inventor	Patrick Bernardelli	11
Group Art Unit	1614	130
Examiner Name		0\
Attorney Docket Number	A0000135-01-HMB	9

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ2
KN		Masumoto, H., Application of Chemical Cytochrome P-450 Model Systems to Studies On Drug Metabolism, M. Drug Metab. Dispos, 19:768 (1991)	
		Seddon, T., et al., Comparative Drug Metabolism of Diazepam in Hepatocytes Isolated From Man, Rat, Monkey and Dog, Biochem. Phjarmacol., 38:1657 (1989)	
		Chenery, R.J., et al., Diazepam Metabolism in Cultured Hepatocytes from Rat, Rabbit, Dog, Guinea Pig, and Man, R. Drug Metab. Dispo., 15:312 (1987)	
		Andrews, S.M., et al., The metabolism and disposition of [2-14C]diazepam in the streptozotocin-diabetic rat, Xenobitica 14:751 (1984)	
		Schwandt, H.J., et al., Metabolic Rearrangements of 1,4-Benzodiazepine Derivatices, Xenobiotica 4:733 (1974)	
		Ruelius, H.W., et al., Metabolism of Diazepam in Dogs: Transformation to Oxazepam, Arch. Biochem. Biophys., III:376 (1965)	
		Schwartz, M.A., et al., Metabolism of Diazepam in Rat, Dog, and Man, J. Pharmacol. Exp. Ther., 149:423 (1965)	
		Ogawa, A., et al., Benzotrifluoride: A Useful Alternative Solvent for Organic Reactions Currently Conducted in Dichloromethane and Related Solvents, J. Org. Chem., 62:450 (1997)	
		Ono, S., et al., Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily, Xenobiotica, 26:1155 (1996)	
		Dolphin D., et al., Polyhaloporphyrins: Ususal Ligands for Metals and Metal-Catalyzed Oxidations, Acc. Chem. Res., 30:251 (1997)	

Examiner Signature	A	Hebry Men M	Date Considered	May 14, 2003
		1 8-		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.